Heart Technology planning two studies on Rotablator restenosis.
This article was originally published in The Gray Sheet
Executive Summary
HEART TECHNOLOGY ROTABLATOR RESTENOSIS RATES TO BE EVALUATED in two randomized clinical trials planned by the firm. By the end of the first quarter, Heart Technology expects to begin patient enrollment in the "Dilation versus Ablation Restenosis" (DART) study and the "Strategy Trial Comparing Two Rotablator Techniques" (STRATUS).